104:(rDNA) is very useful in creating proteins that are identical when exposed into a plant's. A recombinant DNA is an artificial DNA that is created by combining two or more sequences that would not normally come together. In this way, DNA injected into a plant is turned into recombinant DNA and manipulated. The favorable properties of plants are likely to make the plant systems a useful alternative for small, medium and large scale production throughout the development of new antibody-based pharmaceuticals.
88:. Antibodies produced in plants have many advantages that are beneficial to humans, plants, and the economy as well. They can be purified cheaply and in large numbers. The many seeds of plants allow for ample storage, and they have no risk of transmitting diseases to humans because the antibodies are produced without the need of the
54:
a particular pathogen or toxin. The transgenic plants produce antibodies that are similar to their human counterparts, and following purification, plantibodies can be administered therapeutically to acutely ill patients or prophylactically to at-risk individuals (such as healthcare workers). The term
121:
Plantibodies are close to passing clinical trials and becoming approved commercially because of key points. Plants are more economical than most forms of creating antibodies and the technology for harvesting and maintaining them is already present. Plants also reduce the chance of coming in contact
112:
The main reason plants are being used to produce antibodies is for treatment of illnesses such as immune disorders, cancer, and inflammatory diseases, given the fact that the plantibodies also have no risk of spreading diseases to humans. In the past 2 decades, research has shown that plant-derived
19:
is a medical strategy long employed to provide temporary protection against pathogens. Early implementations involved recovering ostensibly cell-free plasma from the blood of human survivors or from non-human animals deliberately exposed to a specific pathogen or toxin. These approaches resulted in
71:
plant. The plantibodies are then modified by intrinsic plant mechanisms (N-glycosylation). Plantibodies are purified from plant tissues by mechanical disruption and denaturation/removal of intrinsic plant proteins by treatment at high temperature and low pH, as antibodies tend to be stable under
126:, making their antibodies safer to use. Plantibodies can be made at an affordable cost and easier manufacturing due to the availability and relatively easy manipulation of genetic information in crops such as potatoes, soybean, alfalfa, rice, wheat and tobacco.
166:
By being able to genetically alter plants to create specific antibodies, it is easier to produce antibodies that will fight diseases not only for plants but for human as well. For that reason, plantibody applications will move more towards the medicinal field.
134:
Commercial use is not yet legalized, but clinical trials are underway to implement the use of plantibodies for humans as injections. So far, companies have started conducting human tests of pharmaceutical products, creating plantibodies that include:
92:
or infectious microorganisms. Plants could be engineered to produce antibodies which fight off their own plant diseases and pests, for example, nematodes, and eliminate the need for toxic pesticides.
397:
Ayala, Marta; Gavilondo, Jorge; Rodríguez, Meilyn; Fuentes, Alejandro; Enríquez, Gil; Pérez, Lincidio; Cremata, José; Pujol, Merardo (2009). "Production of
Plantibodies in Nicotiana Plants".
542:
487:
100:
Antibodies generated by plants are cheaper, easier to manage, and safer to use than those obtained from animals. The applications are increasing because
76:
resins. Production of antibodies in whole transgenic plants, such as species in the genus
Nicotiana, is cheaper and safer than in cultured animal cells.
72:
these conditions. Antibodies can further be purified away from other acid- and temperature- stable proteins by capture on commercially produced
414:
184:
Amemiya, C. T.; Zilch, A.; Hinds-Frey, K. R.; Litman, R. T.; Roess, W.; Hulst, M.; Haire, R. N.; Shamblott, M. J.; Rast, J. P. (1993-01-01).
575:
548:
565:
517:
Stoger, E; Sack, M; Nicholson, L; Fischer, R; Christou, P (2005). "Recent progress in plantibody technology".
570:
32:
27:
Antibodies (also known as an immunoglobulins) are complex proteins produced by vertebrates that recognize
51:
350:"Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants"
266:
16:
47:
226:
511:
534:
469:
420:
410:
379:
306:
249:
207:
526:
459:
451:
402:
369:
361:
296:
241:
197:
202:
185:
101:
84:
Transgenic plants offer an attractive method for large-scale production of antibodies for
285:"Very-large-scale production of antibodies in plants: The biologization of manufacturing"
31:(or molecular patterns) on pathogens and some dangerous compounds in order to alert the
464:
439:
374:
349:
327:
455:
365:
559:
301:
284:
85:
245:
186:"Phylogenetic diversification of immunoglobulin genes and the antibody repertoire"
406:
158:
68:
21:
530:
73:
538:
473:
424:
383:
310:
253:
211:
67:
A plantibody is produced by insertion of genes encoding antibodies into a
123:
43:
89:
28:
56:
348:
Daniell, Henry; Streatfield, Stephen J; Wycoff, Keith (May 2001).
401:. Methods in Molecular Biology. Vol. 483. pp. 103–134.
512:
https://www.news-medical.net/health/What-is-an-Antibody.aspx
50:
with animal DNA encoding a specific human antibody known to
55:
plantibody and the concept are trademarked by the company
20:
crude purifications of plasma-soluble proteins including
438:
Walmsley, Amanda M; Arntzen, Charles J (April 2003).
283:
Buyel, J.F.; Twyman, R.M.; Fischer, R. (July 2017).
145:
Antibodies to prevent sexually transmitted diseases
8:
440:"Plant cell factories and mucosal vaccines"
267:Plantibody (antibody synthesized by plants)
148:Antibodies for non-Hodgkin's -cell lymphoma
113:antibodies have become easier to produce.
46:that is produced by plants that have been
35:that there are pathogens within the body.
463:
373:
300:
201:
142:Antibody to fight cavity causing bacteria
227:"The Molecular Perspective: Antibodies"
176:
322:
320:
203:10.1093/oxfordjournals.molbev.a040000
7:
225:Goodsell, David S. (December 2001).
14:
444:Current Opinion in Biotechnology
399:Recombinant Proteins from Plants
302:10.1016/j.biotechadv.2017.03.011
190:Molecular Biology and Evolution
154:Anthrax vaccine (from tobacco)
1:
519:Current Pharmaceutical Design
456:10.1016/S0958-1669(03)00026-0
366:10.1016/s1360-1385(01)01922-7
246:10.1634/theoncologist.6-6-547
407:10.1007/978-1-59745-407-0_7
592:
151:Vaccine against HIV virus
531:10.2174/1381612054367535
354:Trends in Plant Science
576:Therapeutic antibodies
328:"Antibodies in plants"
289:Biotechnology Advances
48:genetically engineered
33:adaptive immune system
17:Passive immunization
566:Genetic engineering
157:Antibodies against
139:Hepatitis B vaccine
271:Springer Reference
525:(19): 2439–2457.
416:978-1-58829-978-9
583:
552:
547:
499:
498:
496:
494:
484:
478:
477:
467:
435:
429:
428:
394:
388:
387:
377:
345:
339:
338:
336:
334:
324:
315:
314:
304:
280:
274:
264:
258:
257:
231:
222:
216:
215:
205:
181:
591:
590:
586:
585:
584:
582:
581:
580:
556:
555:
545:
516:
508:
503:
502:
492:
490:
486:
485:
481:
437:
436:
432:
417:
396:
395:
391:
347:
346:
342:
332:
330:
326:
325:
318:
282:
281:
277:
265:
261:
229:
224:
223:
219:
183:
182:
178:
173:
132:
119:
110:
102:recombinant DNA
98:
82:
65:
12:
11:
5:
589:
587:
579:
578:
573:
571:Plant products
568:
558:
557:
554:
553:
514:
507:
506:External links
504:
501:
500:
488:"Plantibodies"
479:
450:(2): 145–150.
430:
415:
389:
360:(5): 219–226.
340:
316:
295:(4): 458–465.
275:
259:
240:(6): 547–548.
234:The Oncologist
217:
175:
174:
172:
169:
162:
161:
155:
152:
149:
146:
143:
140:
131:
128:
118:
115:
109:
106:
97:
94:
81:
78:
64:
61:
13:
10:
9:
6:
4:
3:
2:
588:
577:
574:
572:
569:
567:
564:
563:
561:
550:
544:
540:
536:
532:
528:
524:
520:
515:
513:
510:
509:
505:
489:
483:
480:
475:
471:
466:
461:
457:
453:
449:
445:
441:
434:
431:
426:
422:
418:
412:
408:
404:
400:
393:
390:
385:
381:
376:
371:
367:
363:
359:
355:
351:
344:
341:
329:
323:
321:
317:
312:
308:
303:
298:
294:
290:
286:
279:
276:
272:
268:
263:
260:
255:
251:
247:
243:
239:
235:
228:
221:
218:
213:
209:
204:
199:
195:
191:
187:
180:
177:
170:
168:
164:
160:
156:
153:
150:
147:
144:
141:
138:
137:
136:
129:
127:
125:
116:
114:
107:
105:
103:
95:
93:
91:
87:
86:immunotherapy
79:
77:
75:
70:
62:
60:
58:
53:
49:
45:
41:
36:
34:
30:
25:
23:
18:
522:
518:
491:. Retrieved
482:
447:
443:
433:
398:
392:
357:
353:
343:
331:. Retrieved
292:
288:
278:
270:
262:
237:
233:
220:
196:(1): 60–72.
193:
189:
179:
165:
163:
133:
120:
111:
99:
96:Applications
83:
66:
39:
37:
26:
15:
159:Ebola virus
560:Categories
493:7 November
333:6 November
171:References
117:Commercial
80:Advantages
69:transgenic
63:Production
52:neutralize
40:plantibody
22:antibodies
124:pathogens
74:protein A
549:16873380
539:16026298
474:12732315
425:19183896
384:11335175
311:28347720
254:11743216
44:antibody
29:antigens
465:7135315
375:5496653
212:8450761
130:Outlook
108:Medical
90:antigen
546:
537:
472:
462:
423:
413:
382:
372:
309:
252:
210:
57:Biolex
42:is an
543:INIST
230:(PDF)
122:with
535:PMID
495:2013
470:PMID
421:PMID
411:ISBN
380:PMID
335:2013
307:PMID
250:PMID
208:PMID
527:doi
460:PMC
452:doi
403:doi
370:PMC
362:doi
297:doi
242:doi
198:doi
562::
541:.
533:.
523:11
521:.
468:.
458:.
448:14
446:.
442:.
419:.
409:.
378:.
368:.
356:.
352:.
319:^
305:.
293:35
291:.
287:.
269:,
248:.
236:.
232:.
206:.
194:10
192:.
188:.
59:.
38:A
24:.
551:.
529::
497:.
476:.
454::
427:.
405::
386:.
364::
358:6
337:.
313:.
299::
273:.
256:.
244::
238:6
214:.
200::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.